The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation
| Autor: | T. T. Valiev, A. A. Khachatryan, S. V. Goryacheva, N. A. Batmanova, K. I. Kirgizov, S. R. Varfolomeeva |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Онкогематология, Vol 19, Iss 1, Pp 40-50 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1818-8346 2413-4023 |
| DOI: | 10.17650/1818-8346-2024-19-1-40-50 |
| Popis: | The use of high-effective, multicomponent, risk-adopted chemoimmunotherapy schemes in children with Burkitt lymphoma reached advanced long-term progression-free survival over 90 % even for high risk patients. Unfortunately, conventional therapeutic strategy for relapsed/refractory disease is not accepted, and the effectiveness of carboplat‑in- and gemcitabine-containing regimens is unsatisfactory. Clinical experience of rituximab, ibrutinib and nivolumab in combination with polychemotherapy and own clinical case of successful relapsed Burkitt lymphoma treatment with targeted therapy and following autologous and allogeneic hematopoietic stem cell transplantation are presented. Proposed program could achieve a complete remission of Burkitt lymphoma, but short-term after allogeneic hematopoietic stem cell transplantation diagnosed T-cell precursor acute lymphoblastic leukemia became fatal for the patient. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|